| Market Cap | 8.45M | P/E | - | EPS this Y | 19.40% | Ern Qtrly Grth | - |
| Income | -16.69M | Forward P/E | -1.00 | EPS next Y | 38.70% | 50D Avg Chg | -5.00% |
| Sales | 950.1k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -42.00% |
| Dividend | N/A | Price/Book | 0.54 | EPS next 5Y | - | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 5.53 | Shares Outstanding | 22.23M | 52W Low Chg | 76.00% |
| Insider Own | 7.62% | ROA | -59.54% | Shares Float | 20.01M | Beta | -2.81 |
| Inst Own | 7.10% | ROE | -138.37% | Shares Shorted/Prior | 684.72K/543.31K | Price | 0.56 |
| Gross Margin | 65.67% | Profit Margin | - | Avg. Volume | 3,658,606 | Target Price | 8.75 |
| Oper. Margin | -2,023.69% | Earnings Date | - | Volume | 840,597 | Change | -4.82% |
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.